Reducing the risk of drug-drug interactions: a goal of rational drug development.
Preskorn
S H
SH
Psychiatric Research Institute, St. Francis Regional Medical Center, Wichita, Kan, USA.
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000929:Antidepressive Agents, Tricyclic / Q000493:pharmacokinetics / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases; D019388:Cytochrome P-450 CYP1A2; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects*; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000187:drug effects; D010088:Oxidoreductases / Q000037:antagonists & inhibitors / Q000187:drug effects; D011619:Psychotropic Drugs / Q000493:pharmacokinetics / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors / Q000187:drug effects
D015057:1-Naphthylamine; D000929:Antidepressive Agents, Tricyclic; D001189:Aryl Hydrocarbon Hydroxylases; D019388:Cytochrome P-450 CYP1A2; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D010088:Oxidoreductases; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases; C504573:CYP1A2 protein, human; C045793:CYP2C19 protein, human